Recombinant Human Lysine-Specific Demethylase 6B (KDM6B) Protein (His)

Name: Recombinant Human Lysine-Specific Demethylase 6B (KDM6B) Protein (His)
Brand: Beta LifeScience
SKU: BLC-07443P
Availability: InStock

Greater than 85% as determined by SDS-PAGE.

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Product Overview

Description	Recombinant Human Lysine-Specific Demethylase 6B (KDM6B) Protein (His) is produced by our E.coli expression system. This is a protein fragment.
Purity	Greater than 85% as determined by SDS-PAGE.
Uniprotkb	O15054
Target Symbol	KDM6B
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-6His
Target Protein Sequence	LPREKLNPPTPSIYLESKRDAFSPVLLQFCTDPRNPITVIRGLAGSLRLNLGLFSTKTLVEASGEHTVEVRTQVQQPSDENWDLTGTRQIWPCESSRSHTTIAKYAQYQASSFQESLQEEKESEDEESEEPDSTTGTPPSSAPDPKNHHIIKFGTNIDLSDAKRWKPQLQELLKLPAFMRVTSTGNMLSHVGHTILGMNTVQLYMKVPGSRTPGHQENNNFCSVNINIGPGDCEWFAVHEHYWETISAFCDRHGVDYLTGSWWPILDDLYASNIPVYRFVQRPGDLVWINAGTVHWVQATGWCNNIAWNVGPLTAYQYQLALERYEWNEV
Expression Range	1176-1505aa
Protein Length	Partial
Mol. Weight	41.5 kDa
Research Area	Epigenetics And Nuclear Signaling
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Histone demethylase that specifically demethylates 'Lys-27' of histone H3, thereby playing a central role in histone code. Demethylates trimethylated and dimethylated H3 'Lys-27'. Plays a central role in regulation of posterior development, by regulating HOX gene expression. Involved in inflammatory response by participating in macrophage differentiation in case of inflammation by regulating gene expression and macrophage differentiation. Plays a demethylase-independent role in chromatin remodeling to regulate T-box family member-dependent gene expression by acting as a link between T-box factors and the SMARCA4-containing SWI/SNF remodeling complex.
Subcellular Location	Nucleus.
Protein Families	UTX family
Database References	HGNC: 29012 OMIM: 611577 KEGG: hsa:23135 STRING: 9606.ENSP00000254846 UniGene: Hs.223678

Gene Functions References

The KDM6B inhibitor GSK-J4 perturbed the PMA-mediated differentiation of THP-1 cells. The AURKA inhibitor alisertib accelerates the expression of the H3K27 demethylase KDM6B, dissociating AURKA and YY1 from the KDM6B promoter region and inducing differentiation. PMID: 29477140
The interaction of methyltransferase EZH2 or demethylase JMJD3 on RGMA, RARb2, AR, PGR, and ERa genes in the progression and aggressiveness of prostate cancer. PMID: 29161520
We demonstrate that extraskeletal osteosarcoma (ESOS) may include at least two small subsets: an MDM2-amplified deep soft-tissue ESOS and an H3K27me3-deficient organ-based ESOS PMID: 29489027
Our results demonstrate that in the early stage of sepsis, JMJD3 contributes to high levels of neutrophil mPR3 expression and thereby to the production of the inflammatory cytokine IL-1beta PMID: 29621735
Computational methods identifyied H3(17-33)-derived peptides with improved binding affinity that would allow co-crystallization with the KDM6B catalytic core. A co-crystallized H3(17-33)A21M peptide had interactions between the KDM6B zinc binding domain and the H3(17-23) region. KDM6B uses the zinc binding domain to achieve H3K27me3/me2 specificity. A 1564 His-to-Gln substitution explains its higher affinity than KDM6A. PMID: 29220567
Taken together, the authors propose that the miR-939-Jmjd3 axis perturbs the accessibility of hepatitis B virus enhancer II/core promoter (En II) promoter to essential nuclear factors (C/EBPalpha and SWI/SNF complex) therefore leading to compromised viral RNA synthesis and hence restricted viral multiplication. PMID: 27779233
These results demonstrated that histone demethylase JMJD3 regulates CD11a expression in lupus T cells by affecting the H3K27me3 levels in the ITGAL (CD11a) promoter region, and JMJD3 might thereby serve as a potential therapeutic target for SLE. PMID: 28430662
binding of SMAD2/3, the intracellular effectors of activin signaling, was significantly enriched at the Pmepa1 gene, which encodes a negative feedback regulator of TGF-beta signaling in cancer cells, and at the Kdm6b gene, which encodes an epigenetic regulator promoting transcriptional plasticity. PMID: 26215835
In this study, we showed that aberrantly upregulated JMJD3 exerts an anti-apoptotic effect in diffuse large B-cell lymphoma PMID: 27102442
Our study therefore delineates KDM6B function that links NF-kappaB and MAPK signaling pathway mediating MM cell growth and survival, and validates KDM6B as a novel therapeutic target in MM. PMID: 28487543
Here, we discuss the roles of lysine 27 demethylases, JMJD3 and UTX, in cancer and potential therapeutic avenues targeting these enzymes. Despite a high degree of sequence similarity in the catalytic domain between JMJD3 and UTX, numerous studies revealed surprisingly contrasting roles in cellular reprogramming and cancer, particularly leukemia PMID: 27151432
inhibition of the H3K27 demethylase JMJD3 in naive CD4 T cells demonstrates how critically important molecules required for T cell differentiation, such as JAK2 and IL12RB2, are regulated by H3K27me3. PMID: 28947543
KDM6B expression strongly correlates with ERbeta level in human pleural mesothelioma tumors and cell lines. PMID: 27529370
Low JMJD3 expression is associated with breast cancer. PMID: 28423536
Transient and forced expression of JMJD3c followed by the forced expression of lineage-defining transcription factors enabled the hPSCs to activate tissue-specific genes directly. Study have also shown that the introduction of JMJD3c facilitates the differentiation of hPSCs into functional hepatic cells and skeletal muscle cells. PMID: 27802135
results demonstrate that the regulation of Jmjd3 by STAT3 maintains repression of differentiation specific genes and is therefore important for the maintenance of self-renewal of normal neural and glioblastoma stem cells PMID: 28384648
Data show that histone demethylase JMJD3 was reduced and its target gene Snai1 expression was down-regulated after HOTAIR suppression. PMID: 28177890
The number of Kdm6b-positive chondrocytes was lower in human osteoarthritis cartilage samples. PMID: 28314754
Kdm6a and Kdm6b were found to be significantly overexpressed in Malignant pleural mesothelioma (MPM) at the mRNA level. However, tests examining if targeting therapeutically Kdm6a/b using a specific small molecule inhibitor was potentially useful for treating MPM, revealed that members of the Kdm6 family may not be suitable candidates for therapy PMID: 28197626
Lipopolysaccharide treatment recruited Jmjd3 and NF-kappaB to the promoter region of target genes, suggesting Jmjd3 synergizes with NF-kappaB to activate the expression of target genes. PMID: 28189690
Incubation of nickel chloride upregulated the expression of H3K27me3 demethylase jumonji domain-containing protein 3 (JMJD3) in kidney cancer cells, which was accompanied by the reduction in the protein level of H3K27me3. Enhanced demethylation of H3K27me3 may represent a novel mechanism underlying the carcinogenicity of nickel compounds. PMID: 25427687
JMJD3 gene expression in renal cell carcinoma and bladder cancer. PMID: 27983522
JMJD3 and EZH2 in prostate biopsies also demonstrated an increase of JMJD3 and EZH2 in adenocarcinoma with Gleason score 7 and 8 by comparison with a normal biopsy. PMID: 26871869
Low JMJD3 expression is associated with Colorectal Cancer. PMID: 26416711
JMJD3 up-regulation and NF-kappaB activation occur in the region of the wound edge during keratinocyte wound healing PMID: 26802933
JMJD3 promotes SAHF formation by demethylating RB at K810, which reduce the level of phosphorylation of RB protein at S807/811, and this interplay promotes the formation of senescence-associated heterochromatin foci in senescent WI38 cells. PMID: 25698448
We demonstrate that KDM6B plays a key role in clear cell renal cell carcinoma PMID: 26261509
Findings reveal a novel epigenetic mechanism by which JMJD3 promotes melanoma progression and metastasis. PMID: 26729791
JMJD3 is an epigenetic regulator in development and disease. (Review) PMID: 26193001
KDM6B may act in a pro-apoptotic role in NSCLC. PMID: 26303949
Demethylation of IGFBP5 by Histone Demethylase KDM6B Promotes Mesenchymal Stem Cell-Mediated Periodontal Tissue Regeneration by Enhancing Osteogenic Differentiation and Anti-Inflammation Potentials. PMID: 25827480
Data indicate a reverse correlation between the mRNA levels of histone H3 lysine-27 demethylase (JMJD3) and global histone h3 lysine 27 methylation (H3K27me3). PMID: 25791244
Results show that JMJD3 protein is overexpressed in high-grade glioma cells and correlated with dysfunctional activation of senescence-related processes, including proinflammatory cytokines and stem cell tropism toward tumors. PMID: 25652587
KDM6B is a new hypoxia response gene regulated by HIF-2alpha PMID: 25520177
Subcellular localization of Jmjd3 is dynamically regulated and has pivotal roles for H3K27me3 status. PMID: 24646476
JMJD3 is recruited to p53 responsive elements via its interaction with p53 and therefore could act as a fail-safe mechanism to remove low levels of H3K27me3 and H3K27me2 to allow for efficient acetylation of H3K27. PMID: 24797517
JMJD3 at the nexus of epigenetic regulation of inflammation and the aging process PMID: 24925089
our results propose a significant role for the KDM6B-C/EBPalpha axis in the pancreatic ductal adenocarcinoma phenotype. PMID: 24947179
demonstrated that miR-941 and KDM6B regulated the epithelial-mesenchymal transition process and affected cell migratory/invasive properties PMID: 25049231
Studies indicate that Jmjd3 is able to enhance the polarization of M2 microglia by modifying histone H3K27me3, and it has a pivotal role in the switch of microglia phenotypes that may contribute to the immune pathogenesis of PD. PMID: 24212761
JMJD3 promotes osteogenesis in differentiating human mesenchymal stem cells, with MIR146A regulating JMJD3. PMID: 24726732
Histone demethylase Jmjd3 is required for the development of subsets of retinal bipolar cells. PMID: 24572572
results demonstrated critical role of histone demethylase in epigenetic regulation of odontogenic differentiation of dental MSCs. KDM6B may present potential therapeutic target in regeneration of tooth structures and repair of craniofacial defects. PMID: 24158144
Overexpression of JMJD3 is associated with myelodysplastic syndrome. PMID: 23538751
Data suggest that the suppression of different key inflammatory regulators through JMJD3-attenuation would evaluate potential therapeutic targets and to elucidate the molecular mechanism of JMJD3-knockdown (KD) dependent effects in THP-1 cells. PMID: 23711388
KDM6B contributes to the activation of WNT3 and DKK1 at different differentiation stages when WNT3 and DKK1 are required for mesendoderm and definitive endoderm differentiation. PMID: 22907667
Deregulation of JMJD3 may contribute to gliomagenesis via inhibition of the p53 pathway resulting in a block to terminal differentiation. PMID: 23236496
These data demonstrate a novel role of H3 Lys27 histone methylation in fibrosis in systemic sclerosis. PMID: 22915621
Overexpression of KDM6B induced the expression of mesenchymal genes and promoted epithelial-mesenchymal transition. PMID: 23152497
ATF4-dependent regulation of the JMJD3 gene during amino acid deprivation can be rescued in Atf4-deficient cells by inhibition of deacetylation. PMID: 22955275

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.